Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3305)
All Articles published online
|
Mar 7, 2011 (publication date) through Apr 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Leelawat K, Thongtawee T, Narong S, Subwongcharoen S, Treepongkaruna SA. Strong expression of CD133 is associated with increased cholangiocarcinoma progression. World J Gastroenterol 2011; 17(9): 1192-1198 [PMID: 21448425 DOI: 10.3748/wjg.v17.i9.1192] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v17/i9/1192.htm |
| Number | Citing Articles |
| 1 |
Arthur Zimmermann. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract. 2017; : 605 doi: 10.1007/978-3-319-26956-6_31
|
| 2 |
Anthony T. Ruys, Bas Groot Koerkamp, Jimme K. Wiggers, Heinz-Josef Klümpen, Fiebo J. ten Kate, Thomas M. van Gulik. Prognostic Biomarkers in Patients with Resected Cholangiocarcinoma: A Systematic Review and Meta-analysis. Annals of Surgical Oncology 2014; 21(2): 487 doi: 10.1245/s10434-013-3286-x
|
| 3 |
Thanich Sangsuwannukul, Kamonlapat Supimon, Thaweesak Chieochansin, Kornkan Choomee, Jatuporn Sujjitjoon, Mutita Junking, Pa-thai Yenchitsomanus, Yoshihiko Hirohashi. Antitumor activity of T cells secreting αCD133-αCD3 bispecific T-cell engager against cholangiocarcinoma. PLOS ONE 2022; 17(3): e0265773 doi: 10.1371/journal.pone.0265773
|
| 4 |
Arthur Zimmermann. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract. 2017; : 3 doi: 10.1007/978-3-319-26956-6_1
|
| 5 |
Silvestre Vicent, Ruby Lieshout, Anna Saborowski, Monique M. A. Verstegen, Chiara Raggi, Stefania Recalcati, Pietro Invernizzi, Luc J. W. van der Laan, Domenico Alvaro, Diego F. Calvisi, Vincenzo Cardinale. Experimental models to unravel the molecular pathogenesis, cell of origin and stem cell properties of cholangiocarcinoma. Liver International 2019; 39(S1): 79 doi: 10.1111/liv.14094
|
| 6 |
Jiliang Feng, Dawei Zhao, Fudong Lv, Zhongyu Yuan. Epigenetic Inheritance From Normal Origin Cells Can Determine the Aggressive Biology of Tumor-Initiating Cells and Tumor Heterogeneity. Cancer Control 2022; 29: 107327482210781 doi: 10.1177/10732748221078160
|
| 7 |
De-Qiang Ma, Yin-Hua Zhang, De-Ping Ding, Juan Li, Lin-Li Chen, You-You Tian, Kang-Jian Ao. Effect of Bmi-1-mediated NF-κB signaling pathway on the stem-like properties of CD133+ human liver cancer cells. Cancer Biomarkers 2018; 22(3): 575 doi: 10.3233/CBM-181329
|
| 8 |
Jesus M. Banales, Vincenzo Cardinale, Guido Carpino, Marco Marzioni, Jesper B. Andersen, Pietro Invernizzi, Guro E. Lind, Trine Folseraas, Stuart J. Forbes, Laura Fouassier, Andreas Geier, Diego F. Calvisi, Joachim C. Mertens, Michael Trauner, Antonio Benedetti, Luca Maroni, Javier Vaquero, Rocio I. R. Macias, Chiara Raggi, Maria J. Perugorria, Eugenio Gaudio, Kirsten M. Boberg, Jose J. G. Marin, Domenico Alvaro. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nature Reviews Gastroenterology & Hepatology 2016; 13(5): 261 doi: 10.1038/nrgastro.2016.51
|
| 9 |
Hsing-Ju Wu, Pei-Yi Chu. Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications. International Journal of Molecular Sciences 2019; 20(17): 4154 doi: 10.3390/ijms20174154
|
| 10 |
Hao Peng, Erwei Zhu, Yewei Zhang. Advances of cancer-associated fibroblasts in liver cancer. Biomarker Research 2022; 10(1) doi: 10.1186/s40364-022-00406-z
|
| 11 |
Nikolaos Charalampakis, Georgios Papageorgiou, Sergios Tsakatikas, Rodanthi Fioretzaki, Christo Kole, Stylianos Kykalos, Maria Tolia, Dimitrios Schizas. Immunotherapy for cholangiocarcinoma: a 2021 update. Immunotherapy 2021; 13(13): 1113 doi: 10.2217/imt-2021-0126
|
| 12 |
Xiaobo Cai, Jun Li, Xiaodong Yuan, Jingbo Xiao, Steven Dooley, Xinjian Wan, Honglei Weng, Lungen Lu. CD133 expression in cancer cells predicts poor prognosis of non-mucin producing intrahepatic cholangiocarcinoma. Journal of Translational Medicine 2018; 16(1) doi: 10.1186/s12967-018-1423-9
|
| 13 |
PO ZHAO, XIAOYING LI, YALI LU, LIN LIU. Downregulated expression of PHLDA1 protein is associated with a malignant phenotype of cholangiocarcinoma. Oncology Letters 2015; 10(2): 895 doi: 10.3892/ol.2015.3316
|
| 14 |
Arthur Zimmermann. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract. 2016; : 1 doi: 10.1007/978-3-319-26587-2_31-1
|
| 15 |
Ding-Zhong Peng, Jiong Lu, Bei Li, Hai-Jie Hu, Xi-Wen Ye, Xian-Ze Xiong, Nan-Sheng Cheng. A simple scoring system to predict early recurrence of Bismuth–Corlette type IV perihilar cholangiocarcinoma. Gastroenterology Report 2019; 7(5): 345 doi: 10.1093/gastro/goz012
|
| 16 |
Toshio Kokuryo, Yukihiro Yokoyama, Masato Nagino. Recent advances in cancer stem cell research for cholangiocarcinoma. Journal of Hepato-Biliary-Pancreatic Sciences 2012; 19(6): 606 doi: 10.1007/s00534-012-0542-6
|
| 17 |
Thanich Sangsuwannukul, Kamonlapat Supimon, Jatuporn Sujjitjoon, Nattaporn Phanthaphol, Thaweesak Chieochansin, Naravat Poungvarin, Sopit Wongkham, Mutita Junking, Pa-thai Yenchitsomanus. Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells. International Immunopharmacology 2020; 89: 107069 doi: 10.1016/j.intimp.2020.107069
|
| 18 |
Arthur Zimmermann. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract. 2016; : 1 doi: 10.1007/978-3-319-26587-2_1-1
|
| 19 |
Maurizio Romano, Francesco De Francesco, Enrico Gringeri, Antonio Giordano, Giuseppe A. Ferraro, Marina Di Domenico, Umberto Cillo. Tumor Microenvironment Versus Cancer Stem Cells in Cholangiocarcinoma: Synergistic Effects?. Journal of Cellular Physiology 2016; 231(4): 768 doi: 10.1002/jcp.25190
|
| 20 |
Naoto Koike. Stem Cells and Cancer in Hepatology. 2018; : 211 doi: 10.1016/B978-0-12-812301-0.00011-6
|
| 21 |
Ze-Yu Shuang, Wen-Chao Wu, Jing Xu, Guohe Lin, Yong-Cheng Liu, Xiang-Ming Lao, Limin Zheng, Shengping Li. Transforming growth factor-β1-induced epithelial–mesenchymal transition generates ALDH-positive cells with stem cell properties in cholangiocarcinoma. Cancer Letters 2014; 354(2): 320 doi: 10.1016/j.canlet.2014.08.030
|
| 22 |
Kai-chao Feng, Ye-lei Guo, Yang Liu, Han-ren Dai, Yao Wang, Hai-yan Lv, Jian-hua Huang, Qing-ming Yang, Wei-dong Han. Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma. Journal of Hematology & Oncology 2017; 10(1) doi: 10.1186/s13045-016-0378-7
|
| 23 |
Tatsuzo Mizukami, Hirofumi Kamachi, Tomoko Mitsuhashi, Takahiro Einama, Yutaka Hatanaka, Toshiya Kamiyama, Akinobu Taketomi. Cytoplasmic CD133 expression correlates with histologic differentiation and is a significant prognostic factor in extrahepatic bile duct cancer and gallbladder cancer. Oncology Letters 2018; doi: 10.3892/ol.2018.9499
|
| 24 |
Vincenzo Cardinale, Anastasia Renzi, Guido Carpino, Alessia Torrice, Maria C. Bragazzi, Felice Giuliante, Agostino M. De Rose, Alice Fraveto, Paolo Onori, Chiara Napoletano, Antonio Franchitto, Alfredo Cantafora, GianLuca Grazi, Nicola Caporaso, Giuseppe D'Argenio, Gianfranco Alpini, Lola M. Reid, Eugenio Gaudio, Domenico Alvaro. Profiles of Cancer Stem Cell Subpopulations in Cholangiocarcinomas. The American Journal of Pathology 2015; 185(6): 1724 doi: 10.1016/j.ajpath.2015.02.010
|
| 25 |
Luca Fabris, Domenico Alvaro. The prognosis of perihilar cholangiocarcinoma after radical treatments. Hepatology 2012; 56(3): 800 doi: 10.1002/hep.25808
|